NO963731L - Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister - Google Patents

Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister

Info

Publication number
NO963731L
NO963731L NO963731A NO963731A NO963731L NO 963731 L NO963731 L NO 963731L NO 963731 A NO963731 A NO 963731A NO 963731 A NO963731 A NO 963731A NO 963731 L NO963731 L NO 963731L
Authority
NO
Norway
Prior art keywords
antagonists
obsessive
treatment
compulsive diseases
compulsive
Prior art date
Application number
NO963731A
Other languages
English (en)
Other versions
NO963731D0 (no
Inventor
Christopher Joseph Schmidt
John Herr Kehne
Robert Andrew Padich
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of NO963731D0 publication Critical patent/NO963731D0/no
Publication of NO963731L publication Critical patent/NO963731L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse er rettet mot 5-HT-antagonister og deres anvendelse som midler ved behandling av obsessive-kompulsive sykdommer (OCD). Oppfinnelsen er i særdeleshet rettet mot forbindelsen (+)-a-(2,3-dimetoksy-I fenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol som er et medlem av klassen av 5-HT-antagonister kjent som N-aralkylpiperidinmetanolderivater som er kraftige og selektive inhibitorer av bindingen av serotonin ved 5-HT-resep-i torsetet.
NO963731A 1994-03-09 1996-09-06 Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister NO963731L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/209,084 US5618824A (en) 1994-03-09 1994-03-09 Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
PCT/US1995/001306 WO1995024194A1 (en) 1994-03-09 1995-02-01 Treatment of obsessive-compulsive disorders with 5-ht2 antagonists

Publications (2)

Publication Number Publication Date
NO963731D0 NO963731D0 (no) 1996-09-06
NO963731L true NO963731L (no) 1996-11-06

Family

ID=22777257

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963731A NO963731L (no) 1994-03-09 1996-09-06 Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister

Country Status (15)

Country Link
US (1) US5618824A (no)
EP (1) EP0749309A1 (no)
JP (1) JP3861250B2 (no)
KR (1) KR100360132B1 (no)
CN (1) CN1143321A (no)
AU (1) AU690968B2 (no)
CA (1) CA2183954C (no)
FI (1) FI963511A (no)
HU (1) HU218948B (no)
IL (1) IL112895A (no)
NO (1) NO963731L (no)
NZ (1) NZ281768A (no)
TW (1) TW301606B (no)
WO (1) WO1995024194A1 (no)
ZA (1) ZA951797B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
EP0796619A1 (en) 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
AU2606897A (en) 1996-04-05 1997-10-29 Fmc Corporation Method for preparing spinel li1+xmn2-xo4+y intercalation compounds
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6228864B1 (en) * 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
SE9801516D0 (sv) * 1998-04-30 1998-04-30 Maria Carlsson M100907/4-Piperidinemethanol derivatives for autism
WO2000012090A1 (en) * 1998-08-28 2000-03-09 Aventis Pharmaceuticals Inc. THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
KR100737718B1 (ko) * 1999-07-16 2007-07-11 아벤티스 파마슈티칼스 인크. 황산 모노-[3-(｛1-[2-(4-플루오로-페닐)-에틸]-피페리딘-4-일｝-하이드록시-메틸)-2-메톡시-페닐]에스테르 및 이를 포함하는 약제학적 조성물
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
AU2005309960A1 (en) * 2004-11-22 2006-06-01 Mallinckrodt Inc. Process for the purification of benzphetamine hydrochloride
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
EP3468545A4 (en) 2016-06-08 2020-07-22 President and Fellows of Harvard College METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY RELATED TO AUTISM SPECTRUM DISORDER, RETT SYNDROME AND FRAGILE X SYNDROME
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US20220233133A1 (en) * 2019-05-22 2022-07-28 President And Fellows Of Harvard College Human tactile prepulse inhibition assay
WO2021261471A1 (ja) * 2020-06-23 2021-12-30 国立大学法人京都大学 強迫性障害の治療剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
EP0436245A1 (en) * 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5264576A (en) * 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
US6087346A (en) * 1993-06-23 2000-07-11 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
KR970701544A (ko) 1997-04-12
AU690968B2 (en) 1998-05-07
CA2183954A1 (en) 1995-09-14
NO963731D0 (no) 1996-09-06
HU9602449D0 (en) 1996-11-28
HU218948B (hu) 2001-01-29
JPH09510441A (ja) 1997-10-21
WO1995024194A1 (en) 1995-09-14
CA2183954C (en) 2000-07-18
IL112895A0 (en) 1995-06-29
JP3861250B2 (ja) 2006-12-20
TW301606B (no) 1997-04-01
FI963511A0 (fi) 1996-09-06
EP0749309A1 (en) 1996-12-27
KR100360132B1 (ko) 2003-08-02
US5618824A (en) 1997-04-08
NZ281768A (en) 2001-02-23
IL112895A (en) 1999-12-31
HUT75317A (en) 1997-05-28
AU1869495A (en) 1995-09-25
FI963511A (fi) 1996-09-06
ZA951797B (en) 1996-12-03
CN1143321A (zh) 1997-02-19

Similar Documents

Publication Publication Date Title
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
NO20006482L (no) 4-benzyl piperidinalkylsulfoksy-heterocykler og deres anvendelse som subtype-selektive NMDA reseptorantagonister
AU3492895A (en) Novel substituted piperidines useful for the treatment of allergic diseases
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
DE69105501D1 (de) (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
NO20005454L (no) Nye hydroksyindoler, deres anvendelse som fosfodiesterase 4 inhibitorer og fremgangsmåte for fremstilling derav
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
HK1044282A1 (zh) 作為趨化因子受體活性調節劑的n-脲基烷基-哌啶化合物
NO964871L (no) Nye agonistforbindelser
HK1008819A1 (en) Piperidine derivatives as neurokinin antagonists
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
WO2001098268A3 (en) Piperidine amides as modulators of chemokine receptor activity
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
TR199700956T1 (xx) Indazolkarboksamidler.
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application